This was supposed to be the microbiome’s breakthrough year — and pandemic or not, it looks like it still might be.
Three companies — Finch Therapeutics, Seres Therapeutics, and Rebiotix — said earlier this year that they expected to announce results from pivotal clinical trials for recurrent C. difficile treatments sometime this summer.
For now, those goals seem to be holding. Finch and Seres — along with a dozen others — presented their plans and their pipelines Monday to investors at the second annual Chardan Microbiome Medicines Summit. Seres is still expecting to announce results of its Phase 3 trial in the middle of this year, per its own presentation; Finch said it plans to share data from a Phase 2 trial in the second quarter of this year.
About the Author Reprints
